慢性リンパ性白血病（CLL）市場の機会の評価、疫学、臨床試験、アンメットニーズ、予測（～2032年）

主要7市場（米国、フランス、ドイツ、イタリア、スペイン、英国、日本）のCLLの市場規模は、予測期間（2022年～2032年）の終わりまでに92億米ドルに達し、CAGRで0.9%の成長が予測されています。市場は2022年～2032年に低成長が予測されます。標的薬の併用療法が今後のCLL治療の主流となり、CLL治療情勢においてキメラ抗原受容体（CAR）-T細胞療法が評価されています。

予測期間の主要7市場における主な成長促進要因

• 後期段階にある3つの新規パイプライン薬品の承認
• 価格の高いBreyanziの販売はCLL市場のもっともインパクトのある成長促進要因です。Breyanziは予測期間に主要7市場への上市が見込まれています。
• Brukinsaの日本への上市が見込まれ、米国と欧州5ヶ国での継続的な浸透が売上を牽引する見込みです。

予測期間の主要7市場における市場成長の主な障壁

• 主なBTK阻害薬とVenclextaの特許切れとそれに伴うジェネリックの競合
• 革新的なアプローチがほとんどなく、充実した市場
• 次世代BTK阻害薬の非常に高い価格により、コスト意識の高い市場での普及が阻害される可能性があります。

主なハイライト

• 市場は2022年～2032年に緩やかな成長が見込まれています。慢性リンパ性白血病の主要7市場の市場規模は84億米ドル、2032年までに92億米ドルに達すると予測されています。
• AstraZeneca、Bristol Myers Squibb、Loxo Oncologyが2032年に市場をリードするポジションにつくと予測されます。
• CLLにはアンメットニーズが存在し、特にBTK阻害薬とBCL-2阻害薬で再発した患者が対象です。
• 標的薬の併用療法が今後のCLL治療の主流です。

当レポートでは、慢性リンパ性白血病（CLL）の主要7市場（米国、フランス、ドイツ、イタリア、スペイン、英国、日本）について調査分析し、市場規模と予測、主要動向、競合情勢などを提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 疾患の概要

• 慢性リンパ性白血病（CLL）の概要
• CLLの強み、弱み、機会、脅威の分析
• CLLの分類

第4章 疫学

• CLLの診断された発症数：性別
• CLLの診断された有病数：性別
• CLLの診断された有病数：Raiステージ別
• CLLの診断された発症数の情報源と調査手法
• CLLの診断された有病数と情報源と調査手法
• CLLの診断された有病数の情報源と調査手法：Raiステージ別、Binetステージ別
• CLLの診断された発症数の情報源と調査手法
• CLLの診断された有病数の情報源と調査手法

第5章 現在の治療オプション

• 第一選択療法の治療パラダイム
• 再発または難治性の治療パラダイム
• 現在の治療オプション
• 現在の治療パラダイム
• 現在の治療オプション - KOLの視点
• ブルトン型チロシンキナーゼ阻害薬（Brukinsa、Calquence、Imbruvica）の製品プロファイル
• BCL-2阻害薬Venclextaの製品プロファイル
• PI3K阻害薬の製品プロファイル（Zydelig、Copiktra）
• 抗CD2Oモノクローナル抗体（Gazyva、Rituxan/Mabthera）の製品プロファイル

第6章 アンメットニーズと機会

第7章 研究開発戦略

• CLLの臨床試験デザインの動向
• CLLの取引決定の動向

第8章 パイプラインの評価

• CLLパイプラインの概要
• CLLの後期パイプラインエージェント
• Bristol Myers SquibbのBreyanziの製品プロファイル
• Loxo OncologyのJaypircaの製品プロファイル
• MerckのNemtabrutinibの製品プロファイル

第9章 市場見通し

• CLLの臨床試験：試験スポンサー別
• CLL市場の予測
• 市場の促進要因と障壁

第10章 付録

第11章 連絡先

Abstract

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Chronic Lymphocytic Leukemia (CLL).

These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData's World Markets Healthcare (WMH) and POLI Price Intelligence databases.

This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 7MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Chronic Lymphocytic Leukemia (CLL). These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData's World Markets Healthcare (WMH) and POLI Price Intelligence databases.

CLL develops from the gradual clonal development and buildup of malignant B cells in the bone marrow. They then spread to the blood and secondary lymphoid tissues such as the lymph nodes and spleen. CBy the end of the forecast period, GlobalData forecasts CLL sales to reach $9.2 billion for the 7MM at a low compound annual growth rate (CAGR) of .9%. Slow growth is expected in the chronic lymphocytic leukemia (CLL) market from 2022 to 2032. Targeted drug combinations are the future of CLL treatment and chimeric antigen receptor (CAR)-T cell therapy is being evaluated in the CLL treatment landscape.

Major drivers of growth in the CLL market across the 7MM over the forecast period include the following -

• Approval of three new late-stage pipeline agents
• The sales of high-priced Breyanzi represents the most impactful driver of growth for the CLL market. Breyanzi is anticipated to launch in the 7MM during the forecast period
• The anticipated launch of Brukinsa in Japan and a continued uptake of the drug in the US and 5EU will drive sales

Major barriers to growth in the CLL market across the 7MM over the forecast period include the following:

• Patent expiries with subsequent generic competition for key BTK inhibitors as well as Venclexta
• Well-served market with few innovative approaches
• Extremely high price of next-generation BTK inhibitors could hinder their uptake in cost conscious markets

Key Highlights

• Report deliverables include a Pdf and Excel-based forecast model
• Forecasts includes the 7MM
• Forecasts covers from 2022-2032
• Slow growth is expected in the chronic lymphocytic leukemia (CLL) market from 2022 to 2032. GlobalData valued the Chronic Lymphocytic Leukemia market in the 7MM at $8.4 billion and expects the market to increase to $9.2 billion by 2032
• AstraZeneca, Bristol Myers Squibb, and Loxo Oncology are expected to take market-leading position in 2032
• Unmet needs exist in CLL, particularly for patients who relapse on BTK and BCL-2 inhibitors
• Targeted drug combinations are the future of CLL treatment

Scope

• Overview of Chronic Lymphocytic Leukemia, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized Chronic Lymphocytic Leukemia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Chronic Lymphocytic Leukemia therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Chronic Lymphocytic Leukemia treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
• Analysis of the current and future market competition in the global Chronic Lymphocytic Leukemia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Chronic Lymphocytic Leukemia therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Chronic Lymphocytic Leukemia therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Related Reports
• 1.3. Abbreviations

2. Executive Summary

3. Disease Overview

• 3.1. Overview of Chronic Lymphocytic Leukemia (CLL)
• 3.2. CLL Strenghts, Weaknesses, Opportunities, and Threats Analysis
• 3.3. Classification of CLL

4. Epidemiology

• 4.1. Diagnosed Incident Cases of CLL by Sex
• 4.2. Diagnosed Prevalent Cases of CLL by Sex
• 4.3. Diagnosed Prevalent Cases of CLL by Rai Stage
• 4.4. Sources and Methodology for Diagnosed Incident Cases of CLL
• 4.5. Sources and Methodology for Diagnosed Prevalent Cases of CLL
• 4.6. Sources and Methodology for Diagnosed Prevalent Cases of CLL by Rai Stage and Binet Stage
• 4.7. Sources and Methodology for Diagnosed Incident Cases of CLL
• 4.8. Sources and Methodology for Diagnosed Prevalent Cases of CLL

5. Current Treatment Options

• 5.1. Treatment Paradigm of First-Line Therapy
• 5.2. Treatment Paradigm of Relapsed or Refractory
• 5.3. Current Treatment Options
• 5.4. Current Treatment Paradigm
• 5.5. Current Treatment Options - KOL Perspective
• 5.6. Product Profiles of Bruton's Tyrosine Kinase Inhibitors (Brukinsa, Calquence, Imbruvica)
• 5.7. Product Profile of BCL-2 Inhibitor Venclexta
• 5.8. Product Profiles of PI3K Inhibitors (Zydelig, Copiktra)
• 5.9. Product Profiles of Anti- CD2O Monoclonal Antibodies (Gazyva, Rituxan/ Mabthera)

6. Unmet Needs and Opportunities

7. R&D Strategies

• 7.1. Trends in CLL Clinical Trial Design
• 7.2. Trends in CLL Deal-Making

8. Pipeline Assessment

• 8.1. CLL Pipeline Overview
• 8.2. Late Stage Pipeline Agents for CLL
• 8.3. Product Profile of Bristol Myers Squibb's Breyanzi
• 8.4. Product Profile of Loxo Oncology's Jaypirca
• 8.5. Product Profile of Merck's Nemtabrutinib

9. Market Outlook

• 9.1. CLL Clinical Trials by Trial Sponsors
• 9.2. CLL Market Forecast
• 9.3. Market Drivers and Barriers

10. Appendix

• 10.1. Primary Research - KOL Information
• 10.2. About the Authors

11. Contact Us